Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combined endpoints: can we use them?

Jacobus Lubsen1, Bridget-Anne Kirwan

  • 1SOCAR Research SA, Nyon, Switzerland. jlubsen@compuserve.com

Statistics in Medicine
|September 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stability of nutrients in complex liquid and powder food matrices: learnings from shelf-life studies in foods for special medical purposes.

Current research in food science·2025
Same author

Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial.

The lancet. Diabetes & endocrinology·2024
Same author

Outpatient Randomized Controlled Trials in the Covid-19 Era and Beyond.

NEJM evidence·2024
Same author

Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial.

Cardiovascular diabetology·2023
Same author

Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function.

Clinical journal of the American Society of Nephrology : CJASN·2023
Same author

Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial.

Circulation·2023
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
Same journal

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
See all related articles

Combining non-fatal events with all-cause mortality in clinical trials, especially for cardiovascular disease, provides a more accurate assessment of therapy efficacy. This approach ensures event-free survival is properly evaluated, avoiding spurious conclusions from isolated analyses.

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Cardiovascular Research

Background:

  • Analyzing non-fatal events in isolation can lead to inaccurate conclusions about treatment efficacy.
  • Combined endpoints, including all-cause mortality, are increasingly used in clinical trials, particularly in cardiovascular disease.

Purpose of the Study:

  • To highlight the importance of combining non-fatal events with all-cause mortality for robust efficacy assessment.
  • To demonstrate methods for avoiding analytical distortions when patients are lost to follow-up or die before endpoint measurement.

Main Methods:

  • Utilizing ranked combined endpoints that incorporate both clinical events and paraclinical measures.
  • Distinguishing between pseudo and true intention-to-treat analyses based on patient inclusion criteria.

Related Experiment Videos

Main Results:

  • Combining endpoints addresses event-free survival, a crucial metric for therapy evaluation.
  • Ranked combined endpoints including all patients randomized prevent distortion caused by missing data or patient death.

Conclusions:

  • A true intention-to-treat analysis using ranked combined endpoints ensures accurate evaluation of treatment effects.
  • Proper endpoint analysis is critical for reliable therapeutic decision-making in clinical research.